Breath acetone changes in decompensated heart failure patients on inotropes
- 16 October 2026
- journal article
- Published by IOP Publishing in Journal of Breath Research
- Vol. 20 (4) , 046008
Abstract
Early assessment of treatment response in patients with decompensated heart failure (HF) requiring inotropic support remains challenging. Exhaled breath acetone, a noninvasive marker of ketone body metabolism, may reflect dynamic metabolic changes associated with clinical status. We aimed to evaluate short-term temporal changes in exhaled breath acetone levels following inotropic therapy in patients with decompensated HF. This is a prospective, single-center observational study including patients with HF requiring inotropic therapy. Exhaled breath acetone levels were measured in decompensated HF patients requiring inotropic support using a previously described noninvasive device at hospital admission and within 48 h. The analysis was performed by spectrophotometry after reaction with salicylaldehyde. Ninety-seven patients were enrolled. Baseline median exhaled breath acetone concentration at admission was 7.75 (3.90–12.27) µ g l −1 and decreased to 2.15 (1.10–4.19) µ g l −1 after 48 h of inotrope initiation ( p < 0.001 for within-patient comparison). This reduction was accompanied by clinical improvement in signs of HF decompensation and occurred in patients with or without type 2 diabetes, although the magnitude of this reduction was greater in patients without diabetes ( p = 0.001). Elevated exhaled breath acetone levels were observed in patients with decompensated HF and decreased after initiation of inotropic therapy, paralleling clinical improvement. These findings are hypothesis-generating and larger prospective studies may confirm the potential role of exhaled breath acetone in clinical decision-making.Keywords
This publication has 19 references indexed in Scilit:
- Contemporary American and European Guidelines for Heart Failure ManagementJACC: Heart Failure, 2024
- Worsening of Chronic Heart Failure: Definition, Epidemiology, Management and Prevention. A Clinical Consensus Statement by the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2023
- Circulating ketone bodies and cardiovascular outcomes: the MESA studyEuropean Heart Journal, 2023
- Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF TrialJournal of Cardiac Failure, 2022
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2021
- Exhaled Breath Acetone for Predicting Cardiac and Overall Mortality in Chronic Heart Failure PatientsESC Heart Failure, 2020
- Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection FractionJAMA, 2017
- CYP2E1Drug Metabolism and Disposition, 2007
- Breath acetone in congestive heart failureThe American Journal of Cardiology, 1995
- Aspects of ketogenesis: Control and mechanism of ketone-body formation in isolated RAT-liver mitochondriaMolecular and Cellular Biochemistry, 1975